Fundraising FoxAcer Therapeutics
Cambridge, US · Founded 2013 · Delaware corporation · 1 known investors
Find your way into Acer Therapeutics
Sign up to see every warm intro you have to Acer Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Acer Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Acer Therapeutics was founded in 2013 by Christopher Schelling.
CS
Christopher SchellingFounder
HS
Harry S. PalminExecutive
Board
CL
Cynthia LavoieBoard director
Investors · 1
Funding
SEC filings, press & company announcements$29M disclosed across 4 of 5 rounds · 2015–2023
- Undisclosed amountregistered direct offeringMar 2023Source ↗
▶$15.7MraisedOct 2017 · 10 investors · PharmaceuticalsRule 506(b)
▶$15.7MraisedOct 2017 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert SteinerExecutive Officer
- Christopher SchellingExecutive Officer, Director
- Harry S. PalminExecutive Officer
- John DunnDirector
- Hubert BirnerDirector
- Luc MarengereDirector
- Stephen AselageDirector
- Offering amount
- $15.7M
- Amount sold
- $15.7M
- Sales commissions
- $1.1M
- Finders' fees
- $67.5K
- Proceeds to insiders
- $948K
- Placement agents
- Piper Jaffray & Co.
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$3.1MraisedApr 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$3.1MraisedApr 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John DunnDirector
- Christopher SchellingExecutive Officer, Director, Promoter
- Luc MarengereDirector
- Stephen AselageDirector
- Harry PalminPromoter
- Offering amount
- $5.5M
- Amount sold
- $3.1M
- Proceeds to insiders
- $419K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$8.1MraisedMay 2016 · 6 investors · PharmaceuticalsRule 506(b)
▶$8.1MraisedMay 2016 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John DunnDirector
- Harry S. PalminPromoter
- Christopher SchellingExecutive Officer, Director, Promoter
- Stephen AselageDirector
- Cynthia LavoieDirector
- Luc MarengereDirector
- Offering amount
- $8.1M
- Amount sold
- $8.1M
- Proceeds to insiders
- $740K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$2.1MraisedApr 2015 · 2 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedApr 2015 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Cynthia LavoieDirector
- Harry S. PalminExecutive Officer, Director, Promoter
- Christopher SchellingExecutive Officer, Director, Promoter
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Proceeds to insiders
- $290K
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Acer Therapeutics?
- Acer Therapeutics was founded by Christopher Schelling in 2013.
- Who are Acer Therapeutics's investors?
- Acer Therapeutics's investors include TVM Capital.
- How much funding has Acer Therapeutics raised?
- Acer Therapeutics has disclosed $29M raised across 4 of its 5 known rounds.
- Where is Acer Therapeutics headquartered?
- Acer Therapeutics is headquartered in Cambridge, US.